BPA Call 36E79718A0003-36C26219F0173
Award Date 12/7/18
Potential Completion Date 12/13/20
Potential Value $274K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Los Angeles, CA 90037, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Gilead Sciences Inc., doing business as Gilead, a biopharmaceutical company. The $47,796.92 award is for the supply of the HIV medication Lenacapavir in tablet and injection forms. The contract is issued under Gilead's GSA Schedule 61-IB for Pharmaceuticals and Drugs and does not have a set-aside designation. Gilead provides pharmaceuticals directly to the VA without any subcontractors. This award...
- This is a $47,796.92 firm-fixed-price delivery order awarded to Gilead Sciences Inc. (Gilead) by the U.S. Department of Veterans Affairs (VA) for the pharmaceutical product LENACAPAVIR. The order was placed under Gilead's General Services Administration (GSA) Schedule 61-IB contract for Pharmaceuticals and Drugs. Gilead is a biopharmaceutical company that provides a range of critical medications to federal agencies, including antiviral treatments, cancer immunotherapies, and pulmonary...
- This federal contract award to Actelion Pharmaceuticals US, Inc. provides the Department of Veterans Affairs (VA) Veterans Health Administration with the pulmonary arterial hypertension medications Uptravi (selexipag) in various dosage forms and combinations. The contract is a Blanket Purchase Agreement (BPA) call off the VA and General Services Administration (GSA) Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), with a potential value of $153,562.16. The contract has no set-aside...
- This federal contract award, valued at $98,745.48, was issued by the Veterans Integrated Service Network 20, a component of the U.S. Department of Veterans Affairs (VA), to Actelion Pharmaceuticals US, Inc., a for-profit pharmaceutical manufacturer. The contract is a delivery order under Actelion's existing Federal Supply Schedule (FSS-61-IB) contract with the VA, which has a total potential value of $219,108,390 from August 2024 to July 2029. This delivery order is for the provision of...
- This federal contract award is for the delivery of SULENCA INJ, a pharmaceutical product, to the U.S. Department of Veterans Affairs (VA) through Gilead Sciences Inc., the prime contractor. The contract has a ceiling value of $14,937.69 and was awarded on September 12, 2024 as a firm-fixed-price delivery order under Gilead's General Services Administration (GSA) Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has an ultimate completion date of September 13, 2024 and was...
- This federal contract award was made by the Veterans Integrated Service Network 20, a civilian agency, to Actelion Pharmaceuticals US, Inc., a for-profit pharmaceutical manufacturer. The contract is for the delivery of the drug VELETRI, with a ceiling value of $65,499.96 and an ultimate completion date of September 30, 2026. The contract is a Firm Fixed Price Delivery Order under Actelion's existing Federal Supply Schedule (FSS-61-IB) contract with the Department of Veterans Affairs, valued at...
- This federal contract award to Actelion Pharmaceuticals US, Inc., a for-profit pharmaceutical manufacturer, is for the delivery of VELETRI, a drug used to treat pulmonary arterial hypertension. The $61,047.47 firm fixed-price delivery order is placed against Actelion's Federal Supply Schedule (FSS-61-IB) contract with the Department of Veterans Affairs (VA) and General Services Administration (GSA) for Pharmaceuticals and Drugs. Actelion also holds a $60 million Blanket Purchase Agreement with...
- This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer of medications for rare diseases, particularly pulmonary arterial hypertension. The contract, valued at $63,114.90, is for the supply of the drug Veletri. It is issued against Actelion's $219,108,390 Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) with the VA, which runs from August 1, 2024, to July...
- This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Actelion Pharmaceuticals US, Inc., a for-profit manufacturer of pharmaceuticals and specialty drug therapies. The $132,282.00 delivery order is funded through the VA's Veterans Integrated Service Network 12 and provides Actelion's pulmonary arterial hypertension medications, including Opsumit, Uptravi, Tracleer, and Ventavis, to VA healthcare facilities and federal...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Actelion Pharmaceuticals US, Inc., a large for-profit pharmaceutical manufacturer. The $4,291.97 firm fixed-price contract was awarded under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and does not utilize a small business set-aside. The contract is a Blanket Purchase Agreement (BPA) call for the medication TRSCLEER, which is likely Actelion's drug Tracleer used to treat pulmonary...